Roflumilast in chronic obstructive pulmonary disease: Evidence from large trials

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 3, 2010, Pages 441-449

  Cazzola, Mario ^a   Picciolo, Stefano ^b   Matera, Maria G ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Adverse events; COPD; Exacerbations; Phosphodiesterase 4 inhibitors; Roglumilast

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CILOMILAST; CORTICOSTEROID; CYCLIC AMP; DRUG METABOLITE; PHOSPHODIESTERASE IV; PLACEBO; ROFLUMILAST; ROFLUMILAST N OXIDE; ROLIPRAM; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG FUNCTION; NAUSEA; NAUSEA AND VOMITING; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TREATMENT WITHDRAWAL; WEIGHT REDUCTION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AMINOPYRIDINES; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; DRUG ADMINISTRATION SCHEDULE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT OUTCOME;

EID: 76449090268     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903555201     Document Type: Review

References (44)

1. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax 2004;59:574-580
2. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-2416
3. Cazzola M, Dahl R. Inhaled combination therapy with long acting beta2-agonists and corticosteroids in stable COPD. Chest 2004;126:220-237
4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946
5. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555
6. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-1917
7. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-229
8. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:712-719
9. Matera MG, Cazzola M. New anti-inflammatory approaches in COPD. Drug Discov Today Ther Strateg 2004;1:335-343
10. Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006;117:1237-1243
11. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol 2006;147 (Suppl 1):S252-7
12. Horowski R, Sastre-Y-Hernandez M. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res 1985;38:23-29
13. Torphy TJ, Barnette MS, Underwood DC, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-135
14. Rennard S, Knobil K, Rabe KF, et al. The efficacy and safety of cilomilast in COPD. Drugs 2008;68 (Suppl 2):3-57
15. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-279 (Pubitemid 32242587)
16. Jones NA, Boswell-Smith V, Lever R, Page CP. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005;18:93-101
17. Bundschuh DS, Eltze M, Barsig J, et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-290
18. Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172:848-853
19. Mata M, Sarria B, Buenestado A, et al. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005;60:144-152
20. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365:167-175
21. Grootendorst DC, Gauw SA, Verhoosel RM, et al. The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax 2007;62:1081-1087
22. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-571
23. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555
24. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-161
25. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-694
26. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21:267-272
27. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703
28. Committee for proprietary medicinal products (CPMP). Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD). Available from: http://www.emea.europa.eu/pdfs/ human/ewp/056298en.pdf [Last accessed 18 October 2009]
29. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-469
30. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204-1213
31. Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;2:CD002991
32. Puhan MA, Bachmann LM, Kleijnen J, et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009;7:2
33. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456
34. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
35. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919
36. Hodder R, Kesten S, Menjoge S, et al. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulm Dis 2007;2:157-167
37. Celli B. COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1. Chest 2006;129:5-6
38. van Grunsven PM, van Schayck CP, Derenne JP, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54:7-14
39. Suissa S, McGhan R, Niewoehner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:535-542 (Pubitemid 47547848)
40. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008;155:308-315
41. Barnes PJ. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006;109:238-245
42. Smith SJ, Cieslinski LB, Newton R, et al. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)- 4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 2004;66:1679-1689
43. Underwood DC, Kotzer CJ, Bochnowicz S, et al. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 1994;270:250-259
44. Boswell-Smith V, Spina D, Oxford AW, et al. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy- 2(2,4,6-trimethylphenylimino)- 3-(n-carbamoyl-2-aminoethyl) -3,4,6,7-tetrahydro- 2H-pyrimido[6,1-a] isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6- diisopropylphenoxy)- 9,10-dimethoxy-4H-pyrimido[6,1-a]i soquinolin-4-one]. J Pharmacol Exp Ther 2006;318:840-848